How Digital Health Can Transform The Fight Against Antimicrobial Resistance (AMR)

Posted on March 15, 2026 by admin

Antimicrobial resistance is no longer a slow-burn problem. It’s a global crisis that’s already killing more people than HIV or malaria. The problem is that because there is no single reason, it is a hidden pandemic.

And while we often talk about new antibiotics or better diagnostics, there’s a quiet revolution happening in the background, one driven by data, sensors, and smarter digital tools.

In this article, I’m going to walk you through how digital health technologies can reshape antimicrobial use worldwide, why the current system is failing, and what needs to happen next if we’re serious about turning the tide on Antimicrobial resistance (AMR).

The Scale Of The Problem Humanity Faces

Antimicrobial resistance isn’t a marginal health challenge, it’s already one of the leading global killers, and all the trends point towards its impact worsening without limit.

According to the World Health Organization (WHO) AMR was:

Directly responsible for 1.27 million deaths in 2019
Contributed to nearly 4.95 million deaths globally that same year

This makes AMR one of the top public health threats worldwide, rivaling major pandemics and surpassing diseases like HIV/AIDS or malaria in annual mortality.

Those numbers are not static, they reflect only the snapshot from 2019, and antibiotics have continued to lose efficacy since then.

More recent surveillance shows that one in six bacterial infections confirmed in the lab in 2023 were resistant to standard antibiotic treatment, which is a massive increase in clinical resistance that undermines frontline medical care globally.

The problem is widespread across regions, but not uniform:

In South-East Asia and the Eastern Mediterranean, roughly one in three infections is now resistant to antibiotics
In the African Region, around one in five infections shows resistance, and resistance levels are rising fastest where access to quality diagnostics and regulated prescribing is weakest.

That rising resistance is not just a future project a threat, it’s a current threat which is growing exponentially. The Global Research on Antimicrobial Resistance (GRAM) Project, published in The Lancet, provides the most comprehensive time-series analysis to date. It found that:

AMR has claimed at least 1 million lives annually since 1990
AMR has already accounted for more than 36 million deaths globally since 1990
Annual AMR deaths increased by around 8 % from 1990 to 2021 and without major intervention, the global toll will continue rising sharply
By 2050, annual deaths directly attributable to AMR could reach 1.9 million, up 70 % from 2021

There are also some really troubling demographic shifts buried in the overall numbers.

Over the past three decades, deaths in children under five have declined by more than 50% – which is obviously great news.

But amongst adults aged 70 and older, AMR mortality has increased by more than 80% over the same time period. This makes overall population is increasingly vulnerable as they grow and age, as the pandemic demonstrated.

Economically, this program is colossal and set to grow. Combined costs for healthcare and productivity loss are projected to hit more than $850 billion per year by 2050.

Global GDP (gross domestic product) could be lowered by 5% if this happens, pushing hundreds of millions into poverty at the exact time that AI technology could do the same to hundreds of millions additionally.

The concrete, measurable trends, show that AMR is already killing millions every single year and increasing the severity and prevalence globally.

Areas with the weakest healthcare systems and lowest wealth are hit harder, which has a knock-on effect that then effects more wealthy regions. It truly is a global problem.

Why Digital Health Matters

Digital health technology is a catch-all term, but for antimicrobial use it boils down to one foundational idea: better data leads to better decisions.

Digital tools can improve the speed, accuracy, and consistency of decisions around infection diagnosis, treatment, and prevention.

But to understand how, you need to look at the entire antimicrobial decision-making chain, from the moment a patient first shows symptoms to the decision to stop therapy.

Right now, nearly every part of that chain is missing critical data. Digital health can fill those gaps and we are at the forefront of achieving this.

The Current Weakness In Our Defenses

Surveillance That Can’t Keep Up

Traditional surveillance relies on lab data that’s slow, incomplete, and poorly connected to real-world clinical context.

It’s like tracking a wildfire with last week’s weather report. AI-powered real-time systems exist, but only a few high-income countries can deploy them.

Electronic Health Records That Don’t Talk To Each Other

EHRs could be the backbone of global antimicrobial optimization. Instead, they’re fragmented, inconsistent, and frequently missing key clinical details like comorbidities, drug levels, or even basic follow-up data.

In low-resource settings, many hospitals still run on paper, and even in some developed countries like the UK NHS.

Diagnostics Outpacing Our Ability To Use Them

Rapid molecular tests and genome sequencing are impressive, but they haven’t solved the problem. Why? Because clinicians still need susceptibility data, and MIC testing remains slow, variable, and poorly standardized.

The result is a diagnostic revolution that hasn’t translated into a prescribing revolution and isn’t set to be any time soon.

Clinical Decision Support Stuck In The Past

Most clinical decision support systems fire static rule-based alerts. They don’t adapt. They don’t learn. They don’t connect context. Clinicians learn to ignore them.

Additionally, alert fatigue is real. The same as other global problems, the more often people are alerted the less they pay attention.

Missing The Most Important Data Of All

Three types of key data shape antimicrobial outcomes:

Host factors (comorbidities, immunity, polypharmacy)
Drug factors (exposure levels, pharmacokinetics)
Pathogen factors (phenotype, genotype, virulence)

Almost none of this is routinely collected – which means almost all digital tools metaphorically have one hand tied behind their back.

Where Digital Health Can Truly Change the Game

Despite the challenges, the opportunities are enormous and they split well across several powerful domains.

AI That Actually Supports Real-World Decisions

AI can analyze data in ways that no human ever could. It can:

Predict which patients will deteriorate
Identify likely pathogens before cultures return
Recommend optimal therapy adjustments
Detect transmission hotspots inside hospitals
Forecast AMR trends in near-real time

Some systems already show promise in IV-to-oral switches or identifying high-risk patients. The challenge is feeding AI the right data and doing it without continuing to allow all too common bias into the system.

Wearables That Monitor Recovery And Even Auto-Dose Drug Levels

Wearable tech has gone mainstream, and that’s a gift for infection management.

We can now track:

Vital signs
Activity levels
Physiological recovery
Early warning signals of deterioration

And in early trials, microneedle patches can measure antibiotic levels in real time. Imagine dosing antibiotics based not on population averages, but on a patient’s actual biology. That’s precision antimicrobial therapy.

It’s not a million miles away either. In the past five years significant numbers of people have adopted cheap 24/7 monitoring devices for diabetes using microneedle patches linked to phone apps and wristbands.

Diagnostics That Talk To The Clinical Workflow

Digital integration can transform diagnostics by:

Linking results directly to prescribing systems
Flagging AMR genes instantly
Creating automated alerts for outbreaks
Feeding local resistance patterns back into community health guidelines

However, all of this only works if the data reaches clinicians in a usable form and is then able to be acted upon instantly, which is the gap that will be toughest to bridge.

Telehealth And mHealth Expanding Access

In many LMICs, telehealth isn’t just supplementary, it’s the only way to reach remote communities.

These tools can:

Enable remote prescribing
Link local clinics to central labs
Improve triage
Provide rapid advice for common infections
Expand access to diagnostics that would never reach rural settings otherwise

Doneright, telehealth can close the AMR inequality gap instead of widening it. Although commonly adopted in developed countries like the USA, it is still in its infancy despite a developed digital infrastructure now existing in most countries.

The Data We Actually Need

This is one of the most important arguments that can be made, and it’s often overlooked.

To optimize antimicrobial use, we need a global consensus on the fundamental data variables that matter.

This includes:

Drug exposure (ideally at the infection site)
Organism phenotype + genotype
Host immune status and comorbidities
Environmental and One Health data
Clear, standardized outcome measures (clinical cure, resistance emergence, toxicity)

Right now, none of this is consistent. Without a shared global framework, digital tools will always hit a ceiling.

Despite organizations like WHO, and increasingly aware and alert global medical community, there is no sign that governments intend to put money and resources into developing a consistent global standard.

Let Me Level With You Now

If we want digital health to genuinely optimize antimicrobial use, we need to build the foundation first.That means standardizing data, integrating sectors, empowering LMICs, modernizing regulation, and bringing every relevant field to the same table.

This is the real path forward – not just for digital health, but for controlling antimicrobial resistance as a whole.

And if we get this right, the impact will be enormous. Not just fewer deaths. Not just smarter prescribing. But a global health system that can finally see, predict, and respond to AMR with the precision the problem demands

Final Thoughts

AMR is the kind of problem that slips through the cracks of traditional health systems. It’s invisible, slow to detect, and shaped by forces that no single country can fully control.

Digital health changes that, but we are a million miles away from where we need to be with such a global threat looming over us.

For the first time, we have the tools to measure what matters, predict what’s coming, and personalize treatment at a global scale. But these tools only work if they’re built on good data, deployed equitably, and integrated into real clinical workflows.

If we can get this right, digital health doesn’t just optimize antimicrobial use. It gives us a fighting chance against one of the greatest health threats of our time.

But right now, we haven’t even begun to get fit to run a race, while the threats we face have already left the starting blocks.

Antibiotic Resistance: Why Precision In Infectious Disease Treatment Matters

Posted on March 2, 2026 by admin

Antibiotics are among the most important medical advances of the last century. They have transformed once-life-threatening infections into treatable conditions and remain at the heart of modern healthcare.

However, their effectiveness is increasingly undermined by antibiotic resistance which is having serious real-world consequences, even in developed countries. Everyone is becoming aware of that, as it is publicized in newspapers regularly and general practitioner doctors are becoming more reluctant to prescribe antibiotics for unconfirmed infections.

As an example of this growing real-world problem, over the past decade the bacterial disease gonorrhea has developed resistance to nearly every class of antibiotics historically used to treat it.

By the late 2010s, health agencies in multiple countries reported cases of gonorrhea resistant to ceftriaxone, the last widely recommended first-line treatment. Some cases were effectively untreatable using standard regimens.

This is having serious global impact:

Gonorrhea is a common infection, often asymptomatic
Untreated or unsuccessfully treated infections can lead to infertility, pelvic inflammatory disease, and increased HIV transmission
Resistant strains spread silently through communities
Increased risk of prostate and cervical cancers

Public-health authorities described drug-resistant gonorrhea as a “superbug” threat, prompting emergency updates to treatment guidelines and intensified surveillance.

What it illustrates:

Resistance can undermine even well-established treatment protocols
Species identification alone is insufficient, specific resistant strains are causing the problem
Surveillance and rapid detection are essential to slowing spread

This case is often cited as a warning that antibiotic resistance can turn routine infections into major clinical challenges. It is why our work in delivering precise analysis is so vital and will become even more so in the future.

Understanding Antibiotic Resistance

Antibiotic resistance occurs when bacteria develop the ability to survive exposure to drugs that are designed to kill them or stop their growth.

This resistance can be intrinsic, meaning certain bacteria are naturally unaffected by specific antibiotics, or acquired through abnormal genetic changes. These changes may occur through spontaneous mutations or by the transfer of resistance genes between bacteria.

Once resistance develops, previously effective treatments may no longer work, increasing the risk of prolonged illness, complications, and transmission.

A Growing Global Health Challenge

Antibiotic resistance is now recognized as a major global health concern by the World Health Organization and other major bodies.

Resistant infections are associated with higher rates of treatment failure, longer hospital stays, and increased healthcare costs. In some cases, resistance limits treatment options to older, harsher, or less effective drugs.

Beyond the impact on individual patients, antibiotic resistance poses broader public-health risks. Resistant bacteria can spread within hospitals, communities, and across borders, making local treatment decisions part of a global challenge.

The Clinical Reality: Treating Infections Under Time Pressure

In routine clinical practice, treatment decisions often need to be made quickly.

Traditional microbiological methods rely on growing bacteria in culture and then testing their susceptibility to antibiotics. While highly informative, these processes may take days to complete using standard lab procedures in most developed countries.

As a result, clinicians frequently prescribe antibiotics without full knowledge based on the most likely pathogens and local resistance patterns, mostly before laboratory confirmation is available.

This clinical reality has driven growing interest in diagnostic approaches that can provide earlier insight into both pathogen identity and likely antibiotic response, which could transform our ability to combat disease in the future.

While empiric therapy is often necessary, it carries inherent risks. The chosen antibiotic may not be effective against the infecting organism, or it may be broader than necessary, contributing to unnecessary selective pressure that encourages resistance. It is this problem our work seeks to eradicate.

Why Species Identification Alone Is Often Insufficient

Identifying the bacterial species responsible for an infection is an important step, but it is not always enough to guide optimal patient treatment

Different strains within the same species can vary dramatically in their resistance profiles. Two infections caused by the same bacterial species may respond very differently to the same antibiotic, depending on their genetic makeup.

Increasingly, strain and gene-level information is recognized as critical for understanding resistance patterns that are not visible through species identification alone.

Linking Pathogen Identity To Likely Treatment Response

Improving early treatment decisions depends on understanding not just what organism is present, but how it is likely to respond to therapy.

Additionally, this rapid testing and the harmlessly built into other types of testing regime, for example drug testing. This could aid faster, cheaper, and a more holistic approach to addressing both addiction and responses to illness and infection generated by it.

Going a step further, within the USA, workplace drug testing could also be used to harness this rapid dual approach, and even to spot problems within specific types of standard testing such as urine, hair, or blood.

Advances in molecular diagnostics and genomics make it possible to detect genetic signatures associated with resistance more rapidly than traditional methods. When combined with comprehensive reference data, these signatures can be used to estimate the likelihood that a given antibiotic will be effective on that individual.

Importantly, this approach is designed to support and not the place clinical judgment. Treatment guidance based on genomic information is probabilistic and must always be interpreted within the patient’s broader clinical context.

Antibiotics And Precision Medicine

Antibiotic stewardship seeks to ensure that patients receive the right antibiotic, at the right dose, for the right duration, something that is currently rarely achieved even in a privately managed setting rather than universal public healthcare.

More precise diagnostic information supports stewardship by reducing unnecessary exposure to broad-spectrum antibiotics and enabling targeted therapy when appropriate. This benefits individual patients while also helping to preserve the effectiveness of antibiotics for future use.

Precision medicine in infectious disease applies the same principle, namely, tailoring treatment based on detailed information about the infectious agent, rather than relying solely on population averages.

Such precision medicine first became well known during the pandemic, and rapid and tailored treatments have developed from it, including vaccinations and even personalized cancer treatments.

The Role Of Genomics And Data In Combating Resistance

Genomics has become an increasingly important tool in understanding how antibiotic resistance develops, spreads, and persists across healthcare and community settings.

At the molecular level, resistance is often driven by specific genetic changes, including the acquisition of resistance genes, mutations in drug targets, or mechanisms that alter drug transport and metabolism.

Genomic analysis makes it possible to detect these features directly, providing insight into resistance mechanisms that may not be apparent through standard testing.

Beyond individual cases, genomic data is particularly valuable when examined across large numbers of infections. Aggregating genetic information from many isolates allows patterns to emerge, revealing how specific resistance traits are associated with certain strains, environments, or clinical contexts, allowing individualized analysis and response on a global basis.

One of the key strengths of genomic approaches is their ability to support real-time visibility into the movement of resistant strains. When genomic data is linked with contextual information such as time, location, and clinical setting, it can help identify emerging clusters, transmission routes, and sources of infection.

Such a capability is increasingly important in hospitals and long-term care facilities, where early detection of resistant strains can inform infection control measures and reduce further spread.

Equally important is the role of centralized reference datasets that link genetic signatures with clinically observed resistance patterns. These datasets transform the raw information into data with a clinically meaningful context, allowing diagnostic tools to interpret new data against established knowledge.

Ultimately, genomics and data together offer a framework for moving from reactive responses to proactive resistance management. By integrating genetic insight with clinical, epidemiological, and general data, global health systems gain earlier awareness of emerging threats and a stronger evidentiary basis for treatment decisions and stewardship strategies.

While genomics alone cannot solve antibiotic resistance, it provides a powerful foundation for understanding its complexity and supporting more informed, coordinated efforts to preserve the effectiveness of existing and future antibiotics.

Looking Ahead: Improving First-Line Treatment Decisions

Addressing antibiotic resistance requires coordinated efforts across healthcare, laboratories, public health systems, and research.

If healthcare placed as much emphasis and use the same resources as, for example, private drug testing, then the industry and healthcare globally would be transformed. Where we spend huge amounts of money and effort detecting socially benign substances such as marijuana, we could be transforming infectious disease control instead.

Faster and more precise diagnostic insights can improve our confidence in early treatment decisions, reduce unnecessary antibiotic exposure, and help slow the spread of resistance. As diagnostic technologies continue to advance, integrating genomic insight into routine care has the potential to strengthen both individual patient outcomes and population-level health.

Antibiotic resistance is a complex problem, but improving how infections are identified and treated from the outset is a critical part of the solution – which we are proud to be at the forefront of.